Cite
HARVARD Citation
Ferrari, F. et al. (2015). Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro. Journal of experimental & clinical cancer research. 34 (1), pp. 1-8. [Online].